Pharnext SCA
OTC:PNEXF

Watchlist Manager
Pharnext SCA Logo
Pharnext SCA
OTC:PNEXF
Watchlist
Price: 999 999.9999 USD Market Closed
Market Cap: 6T USD
Have any thoughts about
Pharnext SCA?
Write Note

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value of PNEXF.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PNEXF Intrinsic Value
Not Available
Base Case Scenario
How do you feel about PNEXF?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about Pharnext SCA

Provide an overview of the primary business activities
of Pharnext SCA.

What unique competitive advantages
does Pharnext SCA hold over its rivals?

What risks and challenges
does Pharnext SCA face in the near future?

Show all valuation multiples
for Pharnext SCA.

Provide P/S
for Pharnext SCA.

Provide P/E
for Pharnext SCA.

Provide P/OCF
for Pharnext SCA.

Provide P/FCFE
for Pharnext SCA.

Provide P/B
for Pharnext SCA.

Provide EV/S
for Pharnext SCA.

Provide EV/GP
for Pharnext SCA.

Provide EV/EBITDA
for Pharnext SCA.

Provide EV/EBIT
for Pharnext SCA.

Provide EV/OCF
for Pharnext SCA.

Provide EV/FCFF
for Pharnext SCA.

Provide EV/IC
for Pharnext SCA.

What are the Revenue projections
for Pharnext SCA?

How accurate were the past Revenue estimates
for Pharnext SCA?

What are the Net Income projections
for Pharnext SCA?

How accurate were the past Net Income estimates
for Pharnext SCA?

What are the EPS projections
for Pharnext SCA?

How accurate were the past EPS estimates
for Pharnext SCA?

What are the EBIT projections
for Pharnext SCA?

How accurate were the past EBIT estimates
for Pharnext SCA?

Compare the revenue forecasts
for Pharnext SCA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Pharnext SCA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Pharnext SCA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Pharnext SCA compared to its peers.

Compare the P/E ratios
of Pharnext SCA against its peers.

Discuss the investment returns and shareholder value creation
comparing Pharnext SCA with its peers.

Analyze the financial leverage
of Pharnext SCA compared to its main competitors.

Show all profitability ratios
for Pharnext SCA.

Provide ROE
for Pharnext SCA.

Provide ROA
for Pharnext SCA.

Provide ROIC
for Pharnext SCA.

Provide ROCE
for Pharnext SCA.

Provide Gross Margin
for Pharnext SCA.

Provide Operating Margin
for Pharnext SCA.

Provide Net Margin
for Pharnext SCA.

Provide FCF Margin
for Pharnext SCA.

Show all solvency ratios
for Pharnext SCA.

Provide D/E Ratio
for Pharnext SCA.

Provide D/A Ratio
for Pharnext SCA.

Provide Interest Coverage Ratio
for Pharnext SCA.

Provide Altman Z-Score Ratio
for Pharnext SCA.

Provide Quick Ratio
for Pharnext SCA.

Provide Current Ratio
for Pharnext SCA.

Provide Cash Ratio
for Pharnext SCA.

What is the historical Revenue growth
over the last 5 years for Pharnext SCA?

What is the historical Net Income growth
over the last 5 years for Pharnext SCA?

What is the current Free Cash Flow
of Pharnext SCA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Pharnext SCA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Pharnext SCA

Current Assets 4m
Cash & Short-Term Investments 40k
Receivables 2.6m
Other Current Assets 1.4m
Non-Current Assets 1.1m
PP&E 730k
Other Non-Current Assets 320k
Current Liabilities 10.9m
Accounts Payable 9m
Other Current Liabilities 1.9m
Non-Current Liabilities 24.8m
Long-Term Debt 24.3m
Other Non-Current Liabilities 560k
Efficiency

Earnings Waterfall
Pharnext SCA

Revenue
150k EUR
Operating Expenses
-26.4m EUR
Operating Income
-26.3m EUR
Other Expenses
-5.3m EUR
Net Income
-31.6m EUR

Free Cash Flow Analysis
Pharnext SCA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

PNEXF Profitability Score
Profitability Due Diligence

Pharnext SCA's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

Exceptional ROE
Exceptional ROIC
ROIC is Increasing
Exceptional 3-Years Revenue Growth
33/100
Profitability
Score

Pharnext SCA's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

PNEXF Solvency Score
Solvency Due Diligence

Pharnext SCA's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Short-Term Solvency
Long-Term Solvency
37/100
Solvency
Score

Pharnext SCA's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PNEXF Price Targets Summary
Pharnext SCA

There are no price targets for PNEXF.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for PNEXF?

Click here to dive deeper.

Dividends

Pharnext SCA
does not pay dividends
Shareholder Yield

Current shareholder yield for PNEXF is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Pharnext SCA Logo
Pharnext SCA

Country

France

Industry

Biotechnology

Market Cap

6T USD

Dividend Yield

0%

Description

Pharnext SA develops and manufactures drugs for neurological diseases. The company is headquartered in Suresnes, Ile-De-France. The company went IPO on 2016-07-18. The firm is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The firm's prime focus is on neurodegenerative diseases and metabolic diseases.

Contact

ILE-DE-FRANCE
Suresnes
14 rue de la Republique
+33141092230
www.pharnext.com

IPO

2016-07-18 00:00:00

Employees

19

Officers

Director
Mr. Daniel E. Cohen M.D., Ph.D.
CEO & Chairman
Mr. Hugo Brugiere M.Sc.
Co-Founder, Chairman of Scientific Advisory Board and Director
Mr. Ilya Chumakov D-Sc, Ph.D.
COO & Chief Scientific Officer
Mr. Vincent Serra Ph.D.
Chief Manufacturing Officer & Head of CMC
Mr. Raj Thota M.Sc.
Chief Medical Officer
Mr. Gilbert Wagener M.D., Ph.D.

See Also

Discover More